Abstract
Cortical hubs that link functionally specialized neural systems are crucial for cognition. Evidence suggests that the location and organization of hubs are related to Alzheimer’s disease (AD). However, two issues remain unclear: (i) where and how hubs change in AD, and (ii) whether hubs could be a potential pre-diagnosis biomarker for mild cognitive impairment (MCI) - a prodromal phase of AD. Accordingly, we examined the functional connectivity density (FCD) in two cohorts of resting-state functional magnetic resonance imaging (fMRI) scans (26 AD, 27 controls; 33 AD, 21 controls) and revealed consistently vulnerable FCD hub regions in AD compared with controls: within the default mode network, short-range FCD decreases in the posterior cingulate cortex and increases in the medial prefrontal cortex; within the frontal lobe, long-range FCD increases in the medial prefrontal cortex, superior frontal gyrus and middle frontal gyrus. Furthermore, FCD correlates with cognitive score and could distinguish MCI from controls with high accuracy (71.08% in dataset 1, 81% in dataset 2). By reflecting a robust and reproducible global shift in brain functions, FCD provides an fMRI biomarker for the underlying mechanism in AD.
Keywords: Alzheimer’s disease, biomarker, classification, functional connectivity density, mild cognitive impairment, resting state functional MRI.
Current Alzheimer Research
Title:Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Volume: 12 Issue: 10
Author(s): Xiuchao Sui, Maohu Zhu, Yue Cui, Chunshui Yu, Jing Sui, Xinqing Zhang, Jieqiong Liu, Yunyun Duan, Zengqiang Zhang, Luning Wang, Xi Zhang and Tianzi Jiang
Affiliation:
Keywords: Alzheimer’s disease, biomarker, classification, functional connectivity density, mild cognitive impairment, resting state functional MRI.
Abstract: Cortical hubs that link functionally specialized neural systems are crucial for cognition. Evidence suggests that the location and organization of hubs are related to Alzheimer’s disease (AD). However, two issues remain unclear: (i) where and how hubs change in AD, and (ii) whether hubs could be a potential pre-diagnosis biomarker for mild cognitive impairment (MCI) - a prodromal phase of AD. Accordingly, we examined the functional connectivity density (FCD) in two cohorts of resting-state functional magnetic resonance imaging (fMRI) scans (26 AD, 27 controls; 33 AD, 21 controls) and revealed consistently vulnerable FCD hub regions in AD compared with controls: within the default mode network, short-range FCD decreases in the posterior cingulate cortex and increases in the medial prefrontal cortex; within the frontal lobe, long-range FCD increases in the medial prefrontal cortex, superior frontal gyrus and middle frontal gyrus. Furthermore, FCD correlates with cognitive score and could distinguish MCI from controls with high accuracy (71.08% in dataset 1, 81% in dataset 2). By reflecting a robust and reproducible global shift in brain functions, FCD provides an fMRI biomarker for the underlying mechanism in AD.
Export Options
About this article
Cite this article as:
Sui Xiuchao, Zhu Maohu, Cui Yue, Yu Chunshui, Sui Jing, Zhang Xinqing, Liu Jieqiong, Duan Yunyun, Zhang Zengqiang, Wang Luning, Zhang Xi and Jiang Tianzi, Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666150710111615
DOI https://dx.doi.org/10.2174/1567205012666150710111615 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probiotics as Anti-Helicobacter pylori Agent: State of the Art
Anti-Infective Agents The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Thioguanine, Mercaptopurine: Their Analogs and Nucleosides as Antimetabolites
Current Pharmaceutical Design Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Treatment of Hereditary Angioedema: Current Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Saturation of the Human Phenome
Current Genomics Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry Structural and Functional Role of Gly281 in L-asparaginase from Erwinia carotovora
Protein & Peptide Letters Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance
Current Rheumatology Reviews